531507-00-3Relevant academic research and scientific papers
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535
Duplantier, Allen J.,Dombroski, Mark A.,Subramanyam, Chakrapani,Beaulieu, Aimee M.,Chang, Shang-Poa,Gabel, Christopher A.,Jordan, Crystal,Kalgutkar, Amit S.,Kraus, Kenneth G.,Labasi, Jeff M.,Mussari, Christopher,Perregaux, David G.,Shepard, Rick,Taylor, Timothy J.,Trevena, Kristen A.,Whitney-Pickett, Carrie,Yoon, Kwansik
, p. 3708 - 3711 (2011/07/31)
High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X7 receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein bindi
Benzamide, heteroarylamide and reverse amides
-
, (2008/06/13)
The present invention relates to novel to P2X7 inhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compound
